West Pharmaceutical Services, Inc.
Health Care · Life Sciences Tools & Services
Structural: every injectable biologic - GLP-1s, mAbs, vaccines, cell + gene therapies - needs a primary container closure. $WST is the dominant Western supplier of elastomer stoppers + plungers, with Daikyo a near-duopoly on premium coated formulations.
Switching cost is extreme (regulatory revalidation per product), giving multi-decade stickiness and pricing power on the high-value mix.
- GLP-1 injectable volume ramp ($LLY tirzepatide, $NVO semaglutide) drives multi-year unit + mix tailwind
- Proprietary Products mix shift toward NovaPure / Westar / FluroTec lifts gross margin
- Biologics + cell/gene therapy pipeline expands TAM beyond legacy vaccine/insulin base
- Asset-light moat: tooling + qualifications take 2-3 years to displace
- Capacity expansion (Grand Rapids, Jersey Shore, Waterford) reserved at premium pricing
- Post-COVID destock cycle has been longer + deeper than guided; visibility still choppy
- Customer concentration in top biopharma; loss of a single GLP-1 program is material
- Capex intensity rising as proprietary mix scales; FCF conversion under pressure
- Premium multiple (mid-30s P/E) leaves little room for 2026 guide misses
No major news in the last 7 days for WST - only listicles and opinion pieces, which we filter out by default. See everything anyway.
No key levels recorded for this ticker.